Radiopharm Theranostics Ltd has released a press release.
Presentation - Pivalate achieves positive Phase 2 data
Filed with ASX ·
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
In the deck
Earlier from Radiopharm Theranostics
- Suspension from Official Quotation
- FDA grants rare pediatric disease designation for DUNP19
- FDA grants Orphan drug status to RAD DUNP19 for Osteosarcoma
- RAD Licenses UCLA Dual Action Antibody
- LOI with GenesisCare to start first trial in Australia
Later from Radiopharm Theranostics
- Pivalate achieves positive Phase 2 data in brain mets trial
- Entitlement Offer to raise up to $10 million
- Successful Completion of Institutional Entitlement Offer
- RAD agreement with NorthStar for supply of Actinium-225
- Entitlement Offer - Extension of Retail Offer
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics